French Institute of Health and Medical Research-ko ikertzaileekin lankidetzan egindako argitalpenak (4)

2013

  1. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 15, Núm. 10, pp. 1173-1184

2011

  1. Short-term survival by treatment among patients hospitalized with acute heart failure: The global ALARM-HF registry using propensity scoring methods

    Intensive Care Medicine, Vol. 37, Núm. 2, pp. 290-301

2007

  1. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trials

    Journal of the American Medical Association, Vol. 297, Núm. 12, pp. 1332-1343

2005

  1. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome study with Tolvaptan (EVEREST)

    Journal of Cardiac Failure, Vol. 11, Núm. 4, pp. 260-269